Drugs that contain Olanzapine; Samidorphan L-malate
1. Lybalvi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7956187 | ALKERMES INC | Method for decreasing opioid metabolism |
Oct, 2021
(2 years ago) | |
| US8252929 | ALKERMES INC | 8-carboxamido-2,6-methano-3-benzazocines |
Oct, 2021
(2 years ago) | |
| US7262298 | ALKERMES INC | 4-hydroxybenzomorphans |
Nov, 2025
(1 year, 6 months from now) | |
| US9119848 | ALKERMES INC | Morphinan derivatives for the treatment of drug overdose |
Aug, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11793805 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11351166 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US9126977 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US9517235 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US10716785 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US10300054 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11241425 | ALKERMES INC | Composition for treating mental illness |
Aug, 2031
(7 years from now) | |
| US11185541 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(7 years from now) | |
| US11707466 | ALKERMES INC | Immediate release multilayer tablet |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating schizophrenia in a patient who has previously experienced significant weight gain induced by olanzapine alone by administering a composition comprising olanzapine and samidorphan; M...
Dosage: TABLET;ORAL
More Information on Dosage
LYBALVI family patents
